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INTRODUCTION
Nortriptyline (NT) has been used to treat various forms
of depression, often in conjunction with psychotherapy. Com-
mon adverse effects associated with tricyclic antidepressant
(TCA) therapy include dry mouth, blurred vision, tachycar-
dia, constipation, urinary retention, sedation, and orthostatic
hypotension (1, 2). These usually occur in association with
toxic concentration of TCA.
NT is extensively metabolized in the liver. The main meta-
bolic pathway of NT is benzylic hydroxylation in the C-10
position, mediated by CYP2D6 (1-3). Genetic polymorphism
of CYP2D6 is responsible for the great interindividual vari-
ability in the pharmacokinetics of NT. CYP2D6 poor meta-
bolizers may experience severe adverse effects (4-7), because
of high NT concentrations. Alternatively, NT may be ineffec-
tive in ultrarapid metabolizers of CYP2D6 (4).
In this report, we present a case on NT therapy with CYP2
D6*5/*10B, which results in decreased activity of CYP2D6.
High plasma NT concentrations associated with adverse effects
after standard doses of NT was found in this case.
CASE REPORT
A 54-yr-old man was hospitalized following a suicide at-
tempt. For the last 2 months the patient had suffered from
depression, anxiety, insomnia, and delusion. At the time of
admission, physical examination of this man showed normal
blood pressure, heart rate, and body temperature. His body
weight was 66.8 kg and he was 165.5 cm in height. EKG
finding was unremarkable. Results of routine laboratory tests
were normal.
After initial assessment, he was diagnosed as major depres-
sion with psychotic symptoms. NT (50 mg/day), lorazepam
(1 mg/day), and risperidone (2 mg/day) were initially pre-
scribed. Supportive psychotherapy was also provided. The pa-
tient’s dose of NT was then increased gradually to 100 mg/
day, administered on a divided-dose schedule. Determination
of plasma NT level was performed by high-performance liquid
chromatography using Hewlett Packard 1090 system (He-
wlett Packard GmbH, Waldbronn, Germany). The plasma
concentration of NT after 6 days of treatment with 100 mg
of daily dose was 181.4 ng/mL (recommended therapeutic
range: 50-150 ng/mL).
However, in an attempt to achieve further clinical improve-
ment, the NT dosage was increased to 150 mg/day over 20
days, which resulted in plasma concentrations of 470.6 ng/mL
after 6 days. He reported experiencing dry mouth, constipa-
tion, and dizziness. Because of this unexpectedly high drug
level and worsening of anticholinergic side effects, the patient’s
dosage was reduced to 100 mg/day. The following measure-
ments indicate that NT concentrations were reduced (198.7-
222.7 ng/mL) but still remained higher than the recommend-
ed therapeutic range. The patient was discharged after 1 mon-
th of hospitalization with a maintenance dose of 100 mg/day.
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A Case Report of a Poor Metabolizer of CYP2D6 Presented with
Unusual Responses to Nortriptyline Medication
We present a case with decreased metabolic activity of CYP2D6, a cytochrome
P450 enzyme catalyzing the metabolism of nortriptyline (NT). Conventional dosage
regimen led to toxic plasma concentration of NT and adverse effects such as dry
mouth, constipation, and dizziness in this case with genotype CYP2D6*5/*10B.
This case suggests the clinical usefulness of pharmacogenetic testing in individu-
alized dosage adjustments of NT.
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Accepted : 1 November 2003This patient underwent CYP2D6 genotyping test after
informed consent. CYP2D6 gene was amplified by long PCR,
to analyze all 9 exons of CYP2D6 gene (8). All PCR products
were sequenced using ABI PRISIM BigDye Terminator Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, U.S.A.)
and an ABI Prism 3100 Genetic Analyzer (Applied Biosys-
tems). CYP2D6*5 allele was detected using long PCR as des-
cribed by Hersberger et al. (9). A fragment specific for deletion
of CYP2D6 gene was obtained with the forward primer spe-
cific for exon 9 of CYP2D7 and the reverse primer specific for
the 3′ flanking region of CYP2D6. The patient was found to
have CYP2D6*5/*10B,which results in low CYP2D6 activity
(Fig. 1, 2).
He has been continuing supportive psychotherapy at the
outpatient clinic monthly and remains improved, even though
his NT dose has been reduced to 50 mg/day.
DISCUSSION
Plasma concentrations of TCAs have been found to corre-
late well with drug responses (1). The recommended thera-
peutic plasma levels of NT are between 50 ng/mL and 150
ng/mL (1, 2). Levels above this range have been associated
with an increased incidence of side effects. Generally, medi-
cations of NT begin at low doses (50-75 mg/day). The dose
is then increased gradually to an average dose of 150 mg/day
until the optimal therapeutic range is reached.
However, steady-state concentrations in plasma observed
in the course of treatment with TCAs are poorly related to
the administered dose, and values in patients who were given
similar doses of TCAs can vary from 10- to 35- fold (1-4).
Patients on the same dose can develop sub-optimal, thera-
peutic or toxic concentrations depending on their clearance
rate (1). Interindividual variation in the metabolism of NT
is one of the important determinants for plasma levels or ad-
verse effects of the drugs.
CYP2D6, which is involved in the hepatic metabolism of
NT, contributes to broad interpatient variability. Previous
reports have suggested that the steady-state concentrations
of the drugs were genetically controlled (4-7). Subjects with
more than one inactive CYP2D6 allele demonstrate poor
metabolizer phenotype and develop high plasma NT concen-
trations (5, 7). Accordingly, poor metabolizers of CYP2D6
are more prone to NT overdose.
About 5-10% of Caucasians and 1% of Asians are poor me-
tabolizers with regard to CYP2D6 substrates (4, 10). The fre-
quency of non-functional allele CYP2D6*5, with deletion
of the entire CYP2D6 gene, is 4-6% of the populations (10,
11). CYP2D6*10 is the most prevalent allele in Asians and
its frequency ranges from 38-70% (10-12). CYP2D6*10
allele is associated with significantly reduced metabolic activ-
ity, approximately 60% of normal activity (10).
In this report, the patient revealed decreased CYP2D6
enzyme activity with the genotype of CYP2D6*5/*10B.
Therefore, he attained drug concentrations above the thera-
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Fig. 1. Long PCR analysis of
CYP2D6*5. A 3.2 kb product
represents the deletion of CYP2
D6 gene in this patient (Lane 1,
DNA size marker; lane 2, positive
control; lane 3, negative control;
lane 4, this case).
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Fig. 2. Detection of nucleotide changes by sequencing analysis of CYP2D6 gene. This case has CYP2D6*10B allele with C100T (A), C1039T
(B), G1661C (C), and G4180C (D) substitution.752 S.-Y. Lee, C.-S. Ki, K.S. Hong, et al.
peutic range at the standard doses and might be at a higher
risk of developing adverse reactions. This patient could have
taken appropriate therapeutic changes earlier and maintained
his psychiatric gains at a lower dose, if he had been genotyped
at the beginning of his NT therapy.
Treatment with two or more drugs metabolized by the same
CYP enzyme may result in interactions such as competition
of the enzyme and decreased rates of metabolism (4). Shim
et al. (13) reported that paroxetine, a potent CYP2D6 inhi-
bitor, increased the blood levels of tricyclic antidepressant in
10 Korean schizophrenic patients. As risperidone is a weak
inhibitor of CYP2D6 enzyme and its metabolite is pharma-
cologically equipotent to the parent drug, drug interactions
related to polymorphic metabolism would be expected to have
limited clinical significance (4, 14).
Clinicians are used to adjusting the dose based on clinical
response and plasma drug concentrations. Additional CYP
2D6 genotyping can serve as an important guide for more
rapid dosage adjustment and prediction of drug response in
each individual. CYP2D6 genotyping is recommended to
complement therapeutic drug monitoring especially when
the unusual metabolic capacity of NT is suspected. Moreover,
due to the potential seriousness and cost of adverse effect in-
cluding cardiac toxicity (15), we can emphasize the importance
of CYP2D6 genotyping in dosage adjustment of NT.
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